GGrantIndex
← Leaderboards

Carole L. Cramer

Biodefense Technologies, Inc.

Google Scholar ↗PubMed ↗ORCID ↗
$6,258,095
Attributed
$16,479,992
Total exposure
18
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.6M · FY2012–25
$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,479,992 · 18

By mechanism

R44$12,861,758 · 6
R43$3,058,018 · 10
R21$361,760 · 1
R41$198,456 · 1

Top collaborators

Others in their field

Top investigators on “Lectin”

Research focus

LectinEnzymesTissuesSmall Business Innovation Research GrantMouse ModelUptakeOrganIn VivoCellsProductionAffectMediatingGeneticTechnologyPathologyBrainFamilyPharmaceutical PreparationsCostBaseInnovationMammalian CellHuman GeneticsEnzyme Replacement Therapy

Grant awards (25)

Treatment of GM1 gangliosidosis CNS manifestations by AAV systemic expression of lectin-enhanced enzyme$1,500,000
R44 · FY2025 · NS
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)$1,498,067
R44 · FY2024 · NS
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)$1,500,000
R44 · FY2023 · NS
Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases$295,923
R43 · FY2023 · HD
Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS$390,497
R43 · FY2022 · NS
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$905,262
R44 · FY2021 · HD · contact PI
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$1,144,737
R44 · FY2020 · HD · contact PI
Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery$250,000
R43 · FY2020 · AR · contact PI
Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease$293,232
R43 · FY2019 · HL
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$1,147,007
R44 · FY2018 · NS
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease$1,071,897
R44 · FY2018 · NS
MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme$225,000
R43 · FY2018 · AR
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease$1,366,586
R44 · FY2017 · NS
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$1,237,037
R44 · FY2017 · NS
Enzyme replacement therapy for Sanfilippo A lysosomal rare disease$659,425
R44 · FY2016 · NS
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$225,000
R43 · FY2016 · HD
Enzyme replacement therapy for Sanfilippo A lysosomal rare disease$831,740
R44 · FY2015 · NS
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$185,915
R43 · FY2015 · NS
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$458,316
R43 · FY2014 · NS
Enzyme Replacement Therapy for GM1 Gangliosidosis Lysosomal Rare Disease$225,000
R43 · FY2014 · NS
Targeted Enzyme Replacement Therapy for Rare Forms of Osteogenesis Imperfecta$223,352
R43 · FY2014 · AR
Enzyme Replacement Therapy for Sanfilippo A Lysosomal Rare Disease$285,783
R43 · FY2013 · NS
RTB-mediated delivery: Orchestrating antigen trafficking to enhance cell immunity$191,760
R21 · FY2013 · AI · contact PI
RTB-mediated delivery: Orchestrating antigen trafficking to enhance cell immunity$170,000
R21 · FY2012 · AI · contact PI
NASALLY-DELIVERED MUCOSAL SUBUNIT VACCINE FOR PLAGUE$198,456
R41 · FY2002 · AI